Repligen CEO Olivier Loeillot sells $976,680 in company stock

Repligen Corp's CEO, Olivier Loeillot, sold 5,426 shares of the company's common stock on September 21, 2026, earning $976,680 from the deal. This sale was part of a pre-planned trading strategy known as Rule 10b5-1, which Loeillot established on August 19, 2025. The stock market has seen RGEN shares near their 52-week peak of $192.49, delivering a substantial 51% return for investors over the past year.

However, InvestingPro's analysis indicates that the stock is currently overvalued, placing it among the most overpriced companies that their platform monitors. In a recent SEC filing, Loeillot disclosed the sale of these shares, executed at $180.0 per share, while simultaneously purchasing 5,426 shares via stock options. The latter purchase took place at $141.79 per share, amounting to $769,352.

These options were exercisable from September 3, 2027, and are set to expire on September 3, 2034. After these transactions, Loeillot currently owns 48,369 shares of Repligen Corp directly, in addition to holding 5,426 derivative securities in the form of stock options. Repligen Corp recently reported second-quarter 2026 results that surpassed market anticipations, reporting adjusted earnings of $0.54 per share, outpacing the projected $0.45.

The company's revenue also increased to $204 million, marginally above the estimated $201.47 million, prompting the firm to revise its full-year forecast. Revenue growth was observed across various segments, with significant contributions from Proteins and Process Analytics. Canaccord Genuity has maintained a Hold rating on Repligen and has kept its price target at $145.